Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

ASCENDIS PHARMA A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmarkIFRS Analyst: XBRLDenmarkIFRS

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2017 2017/12 2018 2018/12 2019 2019/12 2020 N/A 2021 N/A 2022 2022/12 2023e N/A 2024e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   2.4% 1.8% 2.7% 0.0% 0.0% 25.4% 22.0% 22.0%   Credit score (0-100)   66 73 62 0 0 2 3 4   Credit rating   BBB A BBB N/A N/A B B B   Credit limit (mEUR)   0.0 0.3 0.0 0.0 0.0 -0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mEUR)  2017 2017/12 2018 2018/12 2019 2019/12 2020 N/A 2021 N/A 2022 2022/12 2023e N/A 2024e N/A Net sales   21 25 40 0 0 105 105 105   Gross profit   21.1 25.3 40.4 0.0 0.0 91.5 0.0 0.0   EBITDA   -23.3 -43.8 -81.7 0.0 0.0 -178 0.0 0.0   EBIT   -23.3 -43.8 -81.7 0.0 0.0 -178 0.0 0.0   Pre-tax profit (PTP)   -31.9 -13.2 -54.5 0.0 0.0 -143.1 0.0 0.0   Net earnings   -31.1 -12.4 -55.4 0.0 0.0 -142.9 0.0 0.0   Pre-tax profit without non-rec. items   -31.9 -13.2 -54.5 0.0 0.0 -143 0.0 0.0     See the entire income statement 1.0 Balance sheet (mEUR)  2017 2017/12 2018 2018/12 2019 2019/12 2020 N/A 2021 N/A 2022 2022/12 2023e N/A 2024e N/A Tangible assets total   0.3 1.0 11.8 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   376 586 1,066 0.0 0.0 0.0 0.0 0.0   Interest-bearing liabilities   10.4 17.5 24.2 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   406 628 1,130 0.0 0.0 0.0 0.0 0.0   Net Debt   -171 -234 -543 0.0 0.0 0.0 0.0 0.0     See the entire balance sheet 1.0 Volume  2017 2017/12 2018 2018/12 2019 2019/12 2020 N/A 2021 N/A 2022 2022/12 2023e N/A 2024e N/A Net sales   21 25 40 0 0 105 105 105   Net sales growth   36.7% 19.9% 59.9% -100.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   21.1 25.3 40.4 0.0 0.0 91.5 0.0 0.0   Gross profit growth   36.7% 19.9% 59.9% -100.0% 0.0% 0.0% -100.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   406 628 1,130 0 0 0 0 0   Balance sheet change%   39.2% 54.7% 79.8% -100.0% 0.0% 0.0% 0.0% 0.0%   Added value   -23.3 -43.8 -81.7 0.0 0.0 -177.9 0.0 0.0   Added value %   -110.4% -173.2% -202.0% 0.0% 0.0% -168.9% 0.0% 0.0%   Investments   -0 1 11 -12 0 0 0 0   Net sales trend   2.0 3.0 4.0 -1.0 0.0 0.0 0.0 0.0   EBIT trend   -4.0 -5.0 -5.0 0.0 0.0 -1.0 0.0 0.0   1.0 Profitability  2017 2017/12 2018 2018/12 2019 2019/12 2020 N/A 2021 N/A 2022 2022/12 2023e N/A 2024e N/A EBITDA %   -110.4% -173.2% -202.0% 0.0% 0.0% -168.9% 0.0% 0.0%   EBIT %   -110.4% -173.2% -202.0% 0.0% 0.0% -168.9% 0.0% 0.0%   EBIT to gross profit (%)   -110.4% -173.2% -202.0% 0.0% 0.0% -194.5% 0.0% 0.0%   Net Earnings %   -147.6% -49.1% -137.0% 0.0% 0.0% -135.6% 0.0% 0.0%   Profit before depreciation and extraordinary items %   -147.6% -49.1% -137.0% 0.0% 0.0% -135.6% 0.0% 0.0%   Pre tax profit less extraordinaries %   -151.1% -52.0% -134.7% 0.0% 0.0% -135.8% 0.0% 0.0%   ROA %   -5.4% -2.5% -6.1% 0.0% 0.0% 0.0% 0.0% 0.0%   ROI %   -5.6% -2.6% -6.3% 0.0% 0.0% 0.0% 0.0% 0.0%   ROE %   -9.6% -2.6% -6.7% 0.0% 0.0% 0.0% 0.0% 0.0%   1.0 Solidity  2017 2017/12 2018 2018/12 2019 2019/12 2020 N/A 2021 N/A 2022 2022/12 2023e N/A 2024e N/A Equity ratio %   92.5% 93.3% 94.3% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative indebtedness %   144.3% 166.3% 158.2% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   -716.2% -829.3% -1,243.9% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   734.6% 534.8% 664.4% 0.0% 0.0% 0.0% 0.0% 0.0%   Gearing %   2.8% 3.0% 2.3% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   142.9% 2.7% 4.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1.0 Liquidity  2017 2017/12 2018 2018/12 2019 2019/12 2020 N/A 2021 N/A 2022 2022/12 2023e N/A 2024e N/A Quick Ratio   6.0 6.0 10.5 0.0 0.0 0.0 0.0 0.0   Current Ratio   6.0 6.0 10.5 0.0 0.0 0.0 0.0 0.0   Cash and cash equivalent   181.5 251.8 567.1 0.0 0.0 0.0 0.0 0.0   1.0 Capital use efficiency  2017 2017/12 2018 2018/12 2019 2019/12 2020 N/A 2021 N/A 2022 2022/12 2023e N/A 2024e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   868.2% 1,005.0% 1,412.6% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   152.7 212.1 517.0 0.0 0.0 0.0 0.0 0.0   Net working capital %   723.9% 838.7% 1,278.2% 0.0% 0.0% 0.0% 0.0% 0.0%   1.0 Employee efficiency  2017 2017/12 2018 2018/12 2019 2019/12 2020 N/A 2021 N/A 2022 2022/12 2023e N/A 2024e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0